Results for outcome quality of life*
| Baseline predictors (within 6 months after diagnosis) | Number of studies | ||||||
|---|---|---|---|---|---|---|---|
| − | <† | NS | S† | >† | + | References | |
| Demographics | |||||||
| Gender: female | 3 | 36, 50, 56 | |||||
| Higher age at onset | 3 | 36, 50, 53 | |||||
| Higher age at diagnosis | 1 | 56 | |||||
| Longer time from onset to diagnosis | 1 | 36 | |||||
| JIA category‡ | 2 | 1/0 | 36, 50, 53 | ||||
| Disease activity | |||||||
| Higher active joint count | 1 | 1/0 | 1 | 36, 50, 53 | |||
| Higher limited joint count | 0/1 | 1 | 36, 50 | ||||
| Higher articular severity score | 1/0 | 53 | |||||
| Higher PGA | 0/1 | 36 | |||||
| Higher parent/patient GA | 1/0 | 36 | |||||
| Higher pain VAS | 1 | 36 | |||||
| Higher CHAQ score | 1/0 | 36 | |||||
| Higher JAQQ score | 1 | 36 | |||||
| Hand involvement | 1 | 53 | |||||
| Symmetric involvement | 1 | 53 | |||||
| Laboratory | |||||||
| ANA positive | 2 | 50, 53 | |||||
| RF positive | 1/0 | 1 | 50, 53 | ||||
| Higher ESR | 1 | 2 | 36, 50, 53 | ||||
| Higher CRP | 1 | 36 | |||||
| Higher albumin level | 1 | 53 | |||||
| Genetics | |||||||
| HLA-B5 (51,52) | 1 | 53 | |||||
| HLA-B8 | 1 | 53 | |||||
| HLA-B35 | 1 | 53 | |||||
| HLA-C3 (9,10) | 1 | 53 | |||||
| HLA-DR1 (15,16) | 1 | 53 | |||||
| HLA-DR3 (17,18) | 1 | 53 | |||||
| HLA-DR5 (11,12) | 1 | 53 | |||||
| HLA-DQ3 | 1 | 53 | |||||
*Values are the number of studies that found that particular result for the respective predictors. †The first number in this column refers to the number of studies that performed a multivariate analysis disconfirming the univariate finding (studies in which the multivariate analysis confirmed the univariate finding, are shown in the columns labelled − and +, respectively). The second number in this column refers to the number of studies that did not perform a multivariate analysis. ‡In studies that evaluated onset categories oligoarticular, polyarticular and systemic, results have been duplicated for oligoarthritis persistent and extended, and polyarthritis RF-positive and RF-negative, respectively. −, lower chance of favourable outcome in multivariate analysis (p≤0.05); <, lower chance of favourable outcome in univariate analysis (p≤0.05); NS, not significant (p>0.05); S, significant in univariate analysis. Direction of the effect not shown (p≤0.05); >, higher chance of favourable outcome in univariate analysis (p≤0.05); +, higher chance of favourable outcome in multivariate analysis (p≤0.05).
ANA, antinuclear antibodies; CRP, C-reactive protein; CHAQ, childhood health-assessment questionnaire; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigens; JAQQ, juvenile arthritis quality of life questionnaire; JIA, Juvenile idiopathic arthritis; PGA, physician's global assessment; RF, rheumatoid factor; VAS, visual analogue scale.